IBYME   02675
INSTITUTO DE BIOLOGIA Y MEDICINA EXPERIMENTAL
Unidad Ejecutora - UE
artículos
Título:
GALECTINS IN HEMATOLOGICAL MALIGNANCIES
Autor/es:
MIRTA GIORDANO; DIEGO O. CROCI; GABRIEL A. RABINOVICH
Revista:
CURRENT OPINION IN HEMATOLOGY
Editorial:
Lippincott Williams and Wilkins
Referencias:
Lugar: New York; Año: 2013 vol. 20 p. 327 - 335
ISSN:
1531-7048
Resumen:
Purpose of review Galectins are a family of lectin molecules that have emerged as key players in inflammation and tumor progresssion by displaying intracellular and extracellular activities. This review describes the recent advances on the role of galectins in hematological neoplasms. Recent findings Galectin-1 and galectin-3 are the best studied galectins in oncohematology. Increased expression of galectin-1 has been associated with tumor progression in Hodgkin?s lymphoma and chronic lymphocytic leukemia, whereas galectin-3 plays a supporting role in chronic myelogeneous leukemia and multiple myeloma. Functional studies have assigned a key role for galectin-1 as a negative regulator of T-cell immunity in Hodgkin?s lymphoma and cutaneous T-cell lymphoma. Of therapeutic interest is the development of agents with the capacity to interfere with galectin functions. Summary Current knowledge indicates a key role for galectins in hematological neoplasms by favoring the growth and survival of tumor cells and facilitating tumor immune escape. Intervention using specific galectin inhibitors is emerging as an attractive therapeutic option to alter the course of these malignancies. Keywords galectins, Hodgkin?s lymphoma, lymphomas, myeloma, non-Hodgkin?s lymphoma